A microbiologist who left the lab to build the internet's most comprehensive product marketplace for science and engineering professionals - and 25 years later, he's still at the bench, just a different kind.
In 1998, Paul Gatti was a postdoctoral fellow at UCSF, pipetting in the lab and writing grants like every other newly-minted PhD in Microbiology and Immunology from Tulane. Two years later, he co-founded CompareNetworks. It wasn't a pivot so much as a translation - the same instinct that makes a good scientist (rigorous comparison, systematic evaluation, trust in data) turned out to be exactly what the internet was missing for people who buy centrifuges and PCR reagents.
Scientists spending hours hunting for the right antibody or sequencing kit were Gatti's original audience. His insight was specific: research professionals needed better product discovery tools, and the early web wasn't giving them any. Biocompare launched as the answer - a structured, searchable buyer's guide for life science tools, built by someone who had personally felt the friction of the old way.
"At CompareNetworks, our mission has always been to empower professionals with knowledge."- Paul Gatti, CEO, CompareNetworks
What started as a single site became a platform company. Then a multi-brand media company. Then, after a 2019 management buyout backed by Main Street Capital, something more ambitious: a deliberate acquirer of niche B2B media properties across science, engineering, pharma, and eventually energy. The company's portfolio today reads like a taxonomy of industries where professionals need better tools to find better tools: Biocompare for life science, Labcompare for laboratory equipment, American Pharmaceutical Review for pharma manufacturing, GlobalSpec for engineering, SEQanswers for next-gen sequencing, Forensics Magazine, Cell & Gene Therapy Review, DentalCompare, and more.
Gatti has been the quiet constant through all of it. Not a VC-backed unicorn builder. Not a serial-flipper. A company-builder who has compounded one good platform into a dozen over two and a half decades with a team that fits on a single floor of an office building in South San Francisco.
CompareNetworks reaches 2 million professionals every month with $17M annual revenue - and just 62 employees running 12 brands across multiple industries.
The operational math is impressive precisely because it's unpromising on paper. Sixty-two people. Twelve brands. Three hundred million listed products. The leverage comes from the model itself: each brand follows the same playbook - authoritative editorial content, structured product directories, email newsletters, lead generation tools - applied to a new vertical. Gatti doesn't need to reinvent the engine every time. He just parks it in a new garage.
CompareNetworks operates focused B2B media properties across science, engineering, pharma, and energy. Each brand serves a distinct professional audience with product directories, editorial content, and lead generation.
Gatti studied pathogens before studying markets. The same systematic approach he brought to understanding microbial behavior now drives how CompareNetworks builds product taxonomies for 300 million listings.
62 employees. 12 brands. $17M revenue. The revenue-per-employee ratio at CompareNetworks would make most SaaS operators jealous - built on a media-marketplace hybrid model that never went out of fashion.
CompareNetworks raised just $250K in seed funding in 2010. The entire company was bootstrapped for its first decade. Main Street Capital's 2019 buyout was the first institutional capital the founders ever took.
The Gulf Energy Information acquisition in 2025 means CompareNetworks now serves professionals who work with DNA sequencers and oil rigs - possibly the widest professional span in B2B media.
Biocompare, Gatti's flagship brand, has been helping scientists find antibodies, kits, and instruments since 2000 - predating LinkedIn, Twitter, and the iPhone. It still runs 25 years later.
The profile of Paul Gatti you can construct from the outside is defined by what's missing: no splashy fundraising announcements, no conference keynote circuit, no personal brand press machine. He runs a company that reaches millions of professionals every month and has done so, largely quietly, for 25 years.
That's a specific kind of ambition. Not "build it and sell it." Not "raise the next round." Gatti's company-building looks more like a scientific research program - long-horizon, evidence-driven, compound interest in the form of brand equity and audience trust.
The co-founding trio of Gatti, Andy Miller (COO), and Mike Okimoto (Chief Content Officer) has remained intact. That kind of founding team continuity in a 25-year-old company is rare enough to be notable. It suggests a culture more aligned with craft than with the exit.
"We deliver specialized insights, technical expertise, and industry-leading content aimed at accelerating the development of transformative therapies that improve patient outcomes around the world."- Paul Gatti on Cell & Gene Therapy Review, 2024
The move into Cell & Gene Therapy in 2024 offers a useful window into Gatti's editorial instincts. He didn't launch a general biotech trade publication. He launched a quarterly for the specific niche of professionals working on cell and gene therapy R&D and manufacturing - a market small enough to serve with precision, large enough to matter commercially. It's what a scientist would do: identify the specific organism, not the kingdom.
The Gulf Energy Information acquisition in 2025 is harder to read as purely organic - Hydrocarbon Processing is a long way from a PCR kit. But the logic is consistent: trusted editorial content + structured product directories + a captive professional audience. The model travels. Gatti's job is to find the next vertical where it hasn't landed yet.
25 years at one company. The same founding team. Brands that have run for decades. Gatti optimizes for durability, not liquidity.
A PhD scientist who built an information company. His editorial instinct is scientific: specific over general, measurement over intuition.
Uses the same playbook - trusted content + product directory + professional audience - across every vertical he enters.
Millions of users. No celebrity CEO phase. The work speaks instead.
B.S. in Biology
Undergraduate
Ph.D. in Microbiology & Immunology
Graduate Research
Postdoctoral Fellow
1998 - 2000
CompareNetworks is best understood not as a publisher, but as a professional marketplace infrastructure company. Each brand combines three elements: deep editorial content that earns trust, structured product directories that enable comparison, and lead generation tools that connect buyers to sellers.
The business model is B2B media lead generation at scale. Scientists use Biocompare to compare antibodies and kits. Engineers use GlobalSpec to find the right components from 300M+ products. Pharmaceutical manufacturers read American Pharmaceutical Review to stay current on manufacturing best practices. In each case, CompareNetworks' role is to be the trusted intermediary - the place professionals go when the stakes are real and the wrong product choice costs time and money.
The original platform. Antibodies, kits, instruments, sequencing tools. The go-to for bench scientists making product decisions that affect experimental outcomes.
Acquired from IEEE in 2020. Three hundred million industrial and engineering products indexed and searchable. The largest such directory in existence.
Manufacturing, outsourcing, regulatory, and the newest discipline: cell and gene therapy. Launched in 2025 for 33,000 biopharma professionals.
Paul Gatti has been building toward something specific: a professional information company that touches every major sector where technically-trained professionals make product and technology decisions. Life science. Engineering. Pharma. Now energy. The logical next acquisitions write themselves.
CompareNetworks' aspiration - helping professionals "stay informed, discover, and decide" - is a mission statement that scales horizontally. The playbook doesn't change, only the industry does. And every acquisition gives the platform more data, more audience segments to cross-sell, and more credibility with the manufacturers and suppliers who fund it through lead generation.
At 25 years in, Gatti is building something that most media companies can't claim: actual vertical dominance in the markets it serves, with an audience that keeps coming back because the utility is genuine. It started with scientists who needed better antibodies. It's become something considerably larger - and still growing.